MoonLake Immunotherapeutics MLTX
12.62 USD +1.09 (+9.45%)
At closeNov 9, 2026, 4:00 PM EST
12.63 +0.01 +0.08%
After hours · Nov 9, 4:00 PM ET
11.59 Day range 12.91
9.46 52-week range 23.29
- YTD
- -4.25%
- 1 year
- +18.72%
- Market cap
- 1.07B
- EPS (ttm)
- -3.66
- Shares out
- 85.11M
- Forward P/E
- -3.73
- YTD return
- -4.25%
- 1-year return
- +18.72%
- Volume
- 1.56M
- Avg volume
- 1.71M
- Open
- 11.68
- Previous close
- 11.53
- Day's range
- 11.59 – 12.91
- 52-week range
- 9.46 – 23.29
- Beta
- 1.13
- Analysts
- Buy
- Price target
- 30.29 (+140.0%)
- Earnings date
- Nov 4, 2026
5D +1.02 (+8.95%)
Key statistics
- Enterprise value
- 548.34M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.96
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -131.86M
- Total cash
- 537.03M
- Total debt
- 101.53M
- Return on equity
- -67.47%
- Short % of float
- 12.69%
- 50-day average
- 12.11
- 200-day average
- 16.34
Analyst view
Consensus: buy
Buy
Price target (mean) 30.29 +140.0% upside
Now 12.62
- Target (low)
- 6.00
- Target (mean)
- 30.29
- Target (high)
- 57.00
Ratings (0m) 16 12 buy · 2 hold · 2 sell
- Strong buy1
- Buy11
- Hold2
- Sell2
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -0.84714.
Financials — quick view
MLTX Revenue — quarterly 0
MLTX Net income — quarterly -79.55M
MLTX EPS — quarterly -0.93
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -0.77 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.90859 | -0.84 | +0.07 | +7.55% |
| May 11, 2026 | Mar 31, 2026 | -0.91 | -0.98 | -0.07 | -7.69% |
| Feb 25, 2026 | Dec 31, 2025 | -0.92 | -0.92 | 0.00 | 0.00% |
| Nov 5, 2025 | Sep 30, 2025 | -0.89 | -1.10 | -0.21 | -23.60% |
| Aug 5, 2025 | Jun 30, 2025 | -0.73 | -0.87 | -0.14 | -19.18% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 20, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 1, 2026 | Leerink Partners | main | Outperform | Outperform |
| Jun 9, 2026 | BTIG | reit | Buy | Buy |
| Jun 8, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Website
- moonlaketx.com
News
MoonLake Q3 EPS $(0.93) Misses $(0.78) Estimate 
MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update 
What's Going On with MoonLake Immunotherapeutics Stock on Thursday? 
12 Health Care Stocks Moving In Thursday's Intraday Session 
Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday 
HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $50 Price Target - HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $50
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study - MoonLake Immunotherapeutics Reports Topline Results From Phase 3 IZAR-1 Trial Showing Sonelokimab Met All Week 16 Endpoints In Biologic‑Naïve Psoriatic Arthritis Patients
MoonLake Q2 EPS $(0.84) Beats $(0.93) Estimate
Your note
Sign in to keep a note on MLTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BODENSTEDT MATTHIAS | Chief Financial Officer | Sale | Jun 21, 2026 | 1,115,440 |
| BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 30, 2026 | 0 |
| CHEN BIHUA X. | Former | Sale | Sep 29, 2025 | 0 |
| MOUKHEIBIR CATHERINE | Director | Sale | Jul 2, 2025 | 0 |
| REICH KRISTIAN | Officer | Sale | Jul 26, 2026 | 0 |
| SANTOS DA SILVA JORGE | Chief Executive Officer | Sale | Jul 9, 2026 | 2,774,890 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 18.80% | 16,001,284 | 201.94M | Jun 29, 2026 |
| Deep Track Capital, Lp | 8.22% | 6,999,025 | 88.33M | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 5.03% | 4,280,624 | 54.02M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 3.95% | 3,365,507 | 42.47M | Jun 29, 2026 |
| Cormorant Asset Management, LP | 3.77% | 3,205,433 | 40.45M | Jun 29, 2026 |
| Jupiter Topco LLC | 3.63% | 3,085,906 | 38.94M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 1.90% | 1,614,289 | 20.37M | Jun 29, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 1.08% | 918,586 | 11.59M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.93% | 792,072 | 10.00M | Jun 29, 2026 |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 0.71% | 605,474 | 7.64M | Jun 29, 2026 |
| JNL Series Trust-JNL/T. Rowe Price Capital Appreciation Fund | 0.41% | 350,134 | 4.42M | Jun 29, 2026 |
| T. Rowe Price Exch-Trd Fd.s, Inc.-T Rowe Price Capital Appreciation Eq | 0.20% | 167,768 | 2.12M | Jun 29, 2026 |